Skip to main content
Mark Brantly, MD, Pulmonology, Gainesville, FL, UF Health Shands Hospital

MarkLouisBrantlyMD

Pulmonology • Gainesville, FL

Asthma & COPD, Cystic Fibrosis

UF Chief, Pulmonary, Critical Care and Sleep Medicine

Join to view full profile

Dr. Brantly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Brantly's full profile

Already have an account?

Education & Training

  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolResidency, Internal Medicine, 1980 - 1983
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolInternship, Transitional Year, 1979 - 1980
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 1979

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1998 - 2025
  • NC State Medical License
    NC State Medical License 1982 - 2024
  • VA State Medical License
    VA State Medical License 1981 - 2018
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • UF Health Enrolls Its First Patients to Begin Clinical Trials to Treat COVID-19
    UF Health Enrolls Its First Patients to Begin Clinical Trials to Treat COVID-19November 9th, 2020
  • Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”
    Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”November 6th, 2020
  • Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”
    Non-Tuberculous Mycobacterial Lung Disease Due to Multiple “Minor” Risk Factors: An Illustrative Case and a Review of These “Lesser Elements”September 5th, 2020
  • Join now to see all

Grant Support

  • The Miles TrialNational Center For Research Resources2009
  • QuantumNational Center For Research Resources2009
  • Pirfenidone And Patients With Idiopathic Pulmonary Fibrosis (IPF)National Center For Research Resources2009
  • Clinical Trial: Tobacco Smoke Induced Cell Injury In Lung CompartmentsNational Center For Research Resources2008–2009
  • Clinical Trial: Phase I Trial Of Intramuscular Injection Of Raav1-Cb-HaatNational Center For Research Resources2008–2009
  • Clinical Trial: Phase 3 Study Of Safety And Efficacy Of Pirfenidone In PatientsNational Center For Research Resources2008–2009
  • Clinical Trial: Kamada-ApiNational Center For Research Resources2008–2009
  • Alpha-1 Antitrypsin And Macrophage FunctionNational Center For Research Resources2008–2009
  • Clinical Trial: StampNational Center For Research Resources2008
  • Clinical Trial: ChampNational Center For Research Resources2008
  • Tobacco Smoke Induced Cell Injury In Lung CompartmentsNational Center For Research Resources2007
  • StampNational Center For Research Resources2007
  • Phase 3 Study Of Safety And Efficacy Of Pirfenidone In Patients With IPFNational Center For Research Resources2007
  • ChampNational Center For Research Resources2007
  • Genetic Modifiers Of The Alpha1-Antitrypsin DeficiencyNational Center For Research Resources2004–2007
  • FINE Mapping Of COPD Susceptibility GenesNational Center For Research Resources2006
  • Anti-Inflammatory Role Of Alpha-1 Antitrypsin In LungNational Heart, Lung, And Blood Institute2002–2006
  • FINE Mapping Of COPD Susceptability GenesNational Center For Research Resources2005
  • Effect Of Aero, Recomb Alpha 1-Antitrypsin DEF On Epithelial Lining FluidNational Center For Research Resources2005
  • University Of Florida Clinical Research Center DNA, Serum And Plasma BankNational Center For Research Resources2004–2005
  • The Pharmacokinetics And Safety Of An Alpha-1 Proteinase Inhibitor (Arc-Api)National Center For Research Resources2004
  • The Effects Of Atorvastatin On Immune Responses To Tetanus VaccinationNational Center For Research Resources2004
  • Phase 1 Safety Invest Of An Aerosolized, Recomb A1 Antitrypsin In Subj W/ A 1National Center For Research Resources2004
  • 4-Phenyl Butyrate Mediated Secretion Rescue In Alpha 1 Antitrypsin DeficiencyNational Center For Research Resources2004

Hospital Affiliations

Dr. Mark Brantly, Dr. Mark Brantly, MD, Dr. M Brantly, Dr. Mark Louis Brantly